H1 2023 Financial Highlights
Oncology
Key ongoing clinical-trial highlights
TRIAL
POPULATION PATIENTS
DESIGN
Cabometyx
CONTACT-02
2L mCRPC
580
Second novel hormonal
therapy (abiraterone &
prednisone or enzalutamide)
PRIMARY
ENDPOINT(S)
STATUS
Recruiting1
OS, PFS
Phase III
NCT04446117
Onivyde
NAPOLI-3
Phase III
NCT04083235
or
Data anticipated
H2 2023
Cabometyx + atezolizumab
Nab-paclitaxel + gemcitabine
or
1L PDAC
770
OS
Onivyde + 5-FU/LV +
oxaliplatin
U.S. PDUFA date
13 February 2024
R/R FL: following
Tazverik
SYMPHONY-1
Phase III
NCT04224493
at least one prior
systemic
Placebo + R²
chemotherapy,
immunotherapy, or
540
or
Tazverik + R2
PFS
Recruiting1
chemo-
IPSEN
Innovation for patient care
immunotherapy
1. Recruitment status as per ct.gov, June 2023. 2L: second line; mCRPC: metastatic castration-resistant prostate cancer;
OS: overall survival; PFS: progression-free survival; 1L: first line; PDAC: pancreatic ductal adenocarcinoma;
R/R: relapsed/refractory; FL: follicular lymphoma; R2: lenalidomide + rituximab.
26View entire presentation